Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00034203|
Recruitment Status : Completed
First Posted : April 25, 2002
Last Update Posted : June 24, 2005
|Condition or disease||Intervention/treatment||Phase|
|Rheumatoid Arthritis||Drug: efalizumab||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Study Start Date :||April 2002|
|Estimated Study Completion Date :||August 2003|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00034203
Show 52 Study Locations